Schizophrenia Research Trends

110Stephen I. Deutsch, John Mastropaolo and Barbara L. SchwartzREFERENCESAkbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, SandmanCA, Bunney WE Jr., Jones EG. Selective alterations in gene expression for NMDAreceptor subunits in prefrontal cortex of schizophrenics. Journal of Neuroscience 1996;16: 19-30.Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Increased GABA receptorbinding in superficial layers of cingulated cortex in schizophrenics. Journal ofNeuroscience. 1992; 12: 924-929.Billingslea EN, Mastropaolo J, Rosse RB, Bellack AS, Deutsch SI. Interaction of stress andstrain on glutamatergic neurotransmission: Relevance to schizophrenia. PharmacologyBiochemistry and Behavior 2003; 74(2): 351-356.Bonhaus SW, Burge BC, McNamara JO. Biochemical evidence that glycine allostericallyregulates an NMDA receptor-coupled ion channel. Eur J Pharmacol 1987; 142: 489-490.Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Review ofPsychiatry 1996; 3: 241-253.Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. A “glutamatergichypothesis” of schizophrenia: rationale for pharmacotherapy with glycine. ClinicalNeuropharmacology 1989; 12: 1-13.Deutsch SI, Deutsch LH, Weizman R. Nonketotic hyperglycinemia: a paradigm for theapplication of neuroscience to the understanding and treatment of a developmentaldisorder. In: Deutsch SI, Weizman A, Weizman R, eds. Application of basicneuroscience to child psychiatry. New York: Plenum Publishing Corporation, 1990, pp.165-180.Deutsch SI, Hitri A: Measurement of an explosive behavior in the mouse induced by MK-801, A PCP analogue. Clinical Neuropharmacology 1993; 16(3): 251-257.Deutsch SI, Park CH, Lukacs LG, Morn C, Koetzner L, Mastropaolo J. MK-801 alters theGABA A receptor complex and potentiates flurazepam's antiseizure efficacy.Pharmacology Biochemistry and Behavior 1995; 51(4): 909-915.Deutsch SI, Rosse RB, Paul SM, Tomasino V, Koetzner BA, Morn CB, Mastropaolo J. 7-Nitroindazole and metylene blue, inhibitors of neuronal nitric oxide synthase and nostimulatedguanylate cyclase, block MK-801 elicited behaviors in mice.Neuropsychopharmacology 1996; 15: 37-43.Deutsch SI, Rosse RB, Riggs RL, Koetzner L, Mastropaolo J. The competitive NMDAantagonist CPP blocks MK-801-elicited popping behavior in mice.Neuropsychopharmacology 1996; 15:329-331.Deutsch SI, Rosse RB, Paul SM, Riggs RL, Mastropaolo J. Inbred mouse strains differ insensitivity to popping elicited by MK-801. Pharmacology Biochemistry and Behavior;57(1/2): 315-317.Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg P, and Fearing K.Methylene blue adjuvant therapy of schizophrenia. Clinical Neuropharmacology 1997;20(4): 357-363.